Text Size
69 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Re-expression of ER in Triple Negative Breast Cancers
Conditions: Breast Cancer;   Breast Tumors;   Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
22 Recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
23 Recruiting Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab
Conditions: HER2-positive Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Genetic: protein expression analysis;   Other: circulating tumor cell analysis;   Other: diagnostic laboratory biomarker analysis
24 Unknown † Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride
25 Recruiting 18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
26 Recruiting Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate;   Drug: Placebo;   Procedure: Digital mammography;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis;   Procedure: fine-needle aspiration;   Other: pharmacogenomic studies;   Other: questionnaire administration
27 Recruiting Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine;   Biological: Leukine (sargramostim, GM-CSF) and water for injection
28 Recruiting Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
29 Recruiting BIBW 2992 (Afatinib) and Vinorelbine
Condition: Carcinoma Breast Stage IV
Intervention: Drug: BIBW 2992 in combination with vinorelbine
30 Recruiting Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane;   Drug: Carboplatin
31 Recruiting Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
32 Recruiting Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
33 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
34 Not yet recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
35 Recruiting Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast
Condition: Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: therapeutic autologous dendritic cells
36 Recruiting Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
37 Recruiting ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Conditions: Breast Cancer;   Breast Disease;   Neoplasms;   Neoplasms by Site
Intervention: Drug: cyclophosphamide, Adriamycin, Docetaxel, Trastuzumab, Zolendronic acid
38 Recruiting A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin;   Drug: Placebo
39 Recruiting Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Anastrozole+Fulvestrant;   Drug: Tamoxifen
40 Recruiting TKI258 for Metastatic Inflammatory Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Dovitinib
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years